Imidazopyridines
Medchemexpress LLC Linaprazan glurate (X842) | 1228559-81-6 | 99.65% | C26H32N4O5 | 50 MG
Linaprazan glurate (X842) is an orally active prodrug of Linaprazan. It provides a potent and prolonged inhibitory effect on gastric acid secretion by selectively inhibiting acid formation from gastric H⁺/K⁺-ATPase in a potassium-dependent manner. This compound is rapidly transformed by enzymatic cleavage into its active metabolite, linaprazan, and can be used for studies of erosive esophagitis (EE).
- Orally active prodrug
- Potent and prolonged inhibitory effect on gastric acid secretion
- Rapidly transformed into active metabolite, linaprazan
- Selectively inhibits acid formation from gastric H⁺/K⁺-ATPase
- Potassium-dependent mechanism
- Suitable for studies of erosive esophagitis (EE)
Medchemexpress LLC CXCR7 antagonist-1 hydrochloride | 2990472-61-0 | 99.4% | 426.87 | C21H20ClFN6O | 5 MG
CXCR7 antagonist-1 hydrochloride is a research-grade small-molecule antagonist of the CXCR7 (ACKR3) chemokine receptor supplied as its hydrochloride salt. It is used to block CXCL11- and CXCL12-mediated receptor activity in in vitro and preclinical studies.
- Hydrochloride salt for improved solubility and stability.
- High purity (99.41%) suitable for biological assays.
- Molecular weight 426.87; formula C21H20ClFN6O.
- Available as small-mass solid packs and as a DMSO solution.
- Light yellow to green yellow solid; store sealed at 4°C.
- Blocks SDF-1/CXCL12 and I-TAC/CXCL11 binding to CXCR7.
Medchemexpress LLC CXCR7 modulator 1 (compound 25) | 2231812-31-8 | 99.5% | 914.07 | C48H57F2N7O7S | 100 MG
CXCR7 modulator 1 is a potent, orally bioavailable peptoid-hybrid small molecule that modulates the chemokine receptor CXCR7 (reported Ki = 9 nM). It is intended for research use in studies of GPCR signaling and immunology/inflammation.
- Potent CXCR7 modulator with reported Ki of 9 nM.
- Orally bioavailable peptoid-hybrid small molecule.
- Peptoid-hybrid scaffold suitable for medicinal chemistry studies.
- High purity (99.5%) for research applications.
- Molecular weight 914.07, molecular formula C48H57F2N7O7S.
- Suitable for GPCR signaling and immunology or inflammation research.
Medchemexpress LLC HY-100414 1mg Medchemexpress, Soraprazan CAS:261944-46-1 Purity:>98%
Medchemexpress, HY-100414 1mg Soraprazan CAS:261944-46-1 Soraprazan (BYK61359) is a reversible, and fast-acting inhibitor of gastric H + /K + ATPase . Purity:>98% Medchemexpress has over 10000 novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. Other quantity can also be offered.
Medchemexpress LLC Il-17a modulator-1 | 2748749-29-1 | 98.8% | 561.63 g·mol⁻¹ | C33H31N5O4 | 5 MG
IL-17A modulator-1 is a small-molecule research compound that inhibits interleukin-17A (IL-17A) signaling. Reported in patent WO2021239743 (example 9), the compound exhibits potent IL-17A inhibitory activity (pIC50 ≈ 8.2) and is intended for in vitro and preclinical studies of immune-mediated and autoimmune diseases, oncology, and neurodegenerative disorder models.
- Potent IL-17A inhibitory activity (pIC50 ≈ 8.2).
- Suitable for in vitro and preclinical research applications.
- High reported purity for consistent experimental results.
- Available in multiple small-molecule pack sizes for dose-ranging studies.
- Provided with analytical data (COA, LCMS, 1H NMR) for quality control.
Medchemexpress LLC Estrogen receptor modulator 1 | 63676-22-2 | 99.91% | 242.29 | 500 MG
Estrogen receptor modulator 1 (compound 18) is an orally active and selective estrogen receptor modulator (SERM), with a pIC50 of 0.46. It induces regression of Tamoxifen-resistant, hormone independent xenograft tumors.
- Orally active and selective estrogen receptor modulator (SERM).
- Induces regression of Tamoxifen-resistant, hormone independent xenograft tumors.
- Inhibits T47D:A18/PKCα and T47D:A18-TAM1 colony formation at 100 nM for 10 days.
- Significantly inhibits the growth of MCF-7:5C cells and induces apoptosis at 100 nM for 9 days.
- Appearance: Solid, White to off-white.
- Shipping: Room temperature in continental US; may vary elsewhere.
- Storage: Powder at -20°C for 3 years; In solvent at -80°C for 6 months, or -20°C for 1 month.
Medchemexpress LLC Samatasvir | 1312547-19-5 | 99.4% | 885.06 | 5 MG
Samatasvir is a potent, orally active NS5A inhibitor of HCV replication. It is effective and selective against infectious HCV and replicons, with EC50s ranging from 2 to 24 pM in genotype 1 through 5 replicons.
- Potent, orally active NS5A inhibitor of HCV replication.
- Effective and selective against infectious HCV and replicons.
- Retains full activity in the presence of HIV and hepatitis B virus (HBV) antivirals.
- Not cross-resistant with HCV protease, nucleotide, and nonnucleoside polymerase inhibitor classes.
Medchemexpress LLC Az084 | 929300-19-6 | 99.7% | 5 MG
AZ084 is a selective, orally active CCR8 allosteric antagonist for research use. It demonstrates sub-nanomolar potency and is supplied as a high-purity solid suitable for in vitro and in vivo pharmacology studies. Solubility and storage guidance are provided to support experimental formulation and handling.
- Selective CCR8 allosteric antagonist with Ki ≈ 0.9 nM.
- High purity suitable for cellular and pharmacological assays.
- Supplied as a milligram-scale solid for in vitro and in vivo use.
- Highly soluble in DMSO; formulation examples provided for dosing.
- Recommended storage conditions for powder and solutions to preserve stability.
- Intended as a research tool for immunology and inflammation studies.
Medchemexpress LLC Bi-1622 | 2681392-19-6 | 99.0% | 508.53 g/mol | C26H24N10O2 | 10 MG
BI-1622 is an orally active, potent, and highly selective inhibitor of the HER2 (ERBB2) kinase, developed for preclinical research. It has reported biochemical potency (IC50) of 7 nM, shows greater than 25-fold selectivity over EGFR, and has demonstrated efficacy in HER2-driven xenograft models.
Medchemexpress LLC CXCR7 modulator 1 10mg | 2231812-31-8 | 10MG
CXCR7 modulator 1 (compound 25) is a potent and orally bioavailable peptoid hybrid CXCR7 modulator with a Ki of 9 nM[1
Medchemexpress LLC (E)-5-((8-methoxy-2-methylquinolin-4-yl)amino)-N'-(4-(methylthio)benzylidene)-1H-indole-2-carbohydr | 2469975-55-9 | MFCD34167507 | 98.6% | 495.60 g/mol | C28H25N5O2S | 5 MG
Nur77 modulator 1 is a small-molecule ligand that binds the nuclear receptor Nur77 (KD = 3.58 μM). It up-regulates Nur77 expression, alters subcellular localization, induces Nur77-dependent endoplasmic reticulum stress and autophagy, and can lead to apoptosis; reported anti-hepatoma activity. For research use only.
- Binds Nur77 with a KD of 3.58 μM.
- Up-regulates Nur77 expression and alters subcellular localization.
- Induces ER stress and autophagy, leading to apoptosis.
- Reported anti-hepatoma activity in preclinical studies.
- High purity solid suitable for in vitro assays; soluble in DMSO.
- Available in multiple pack sizes for research workflows.
eMolecules AstaTech / OLPRINONE HYDROCHLORIDE HYDRATE / 0.25g / 721754863 / E85868 / 95.000 / 2072803-95-1 / MFCD00946577 / 304.730 / C14H13ClN4O2
AstaTech / OLPRINONE HYDROCHLORIDE HYDRATE / 0.25g / 721754863 / E85868 / 95.000 / 2072803-95-1 / MFCD00946577 / 304.730 / C14H13ClN4O2
![Medchemexpress LLC 4-Oxazolecarboxamide, N-[6-[(2-methoxyethyl)methylamino]-3-pyridinyl]-2-phenyl-5-(trifluoromethyl)- | 939375-07-2 | 99.9% | 420.39 | 5 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000394191.png-250.jpg)
Medchemexpress LLC 4-Oxazolecarboxamide, N-[6-[(2-methoxyethyl)methylamino]-3-pyridinyl]-2-phenyl-5-(trifluoromethyl)- | 939375-07-2 | 99.9% | 420.39 | 5 MG
DGAT1-IN-3 is a potent, selective, and orally bioavailable inhibitor of DGAT-1, with IC50s of 38 nM for human DGAT-1 and 120 nM for rat DGAT-1. It can be used for research on obesity, dyslipidemia, and metabolic syndrome.
- Potent, selective, and orally bioavailable inhibitor of DGAT-1.
- IC50s: 38 nM (human DGAT-1); 120 nM (rat DGAT-1).
- Reduces weight gain and plasma triglycerides, and improves lipid profile in animal models.
- Exhibits good oral bioavailability (77%) and a maximum exposure level in plasma (Cmax) of 24 μM (50 mg/kg; p.o).
- Exhibits terminal elimination half-lives (1.95 h) and low clearance (13.5 mL/min/kg) (5 mg/kg; i.v).
- Appearance: solid, light yellow to yellow color.
Medchemexpress LLC PDE2A-IN-3 | 1426833-08-0 | 295.73 | 50 MG
PDE2A-IN-3 (Example Ic1) is a selective phosphodiesterase 2A (PDE2A) inhibitor with IC50s of 69 nM and 1762 nM for PDE2A and PDE10, respectively. It can be used for the study of neurological and psychiatric disorders.
- Selective phosphodiesterase 2A (PDE2A) inhibitor
- IC50 of 69 nM for PDE2A and 1762 nM for PDE10
- Useful for research into neurological and psychiatric disorders
Medchemexpress LLC DGAT1-IN-3 | 939375-07-2 | 99.9% | 420.39 | 50 MG
DGAT1-IN-3 is a potent, selective and orally bioavailable inhibitor of DGAT-1, with IC50s of 38 nM for human DGAT-1 and 120 nM for rat DGAT-1. It could be used to research of obesity, dyslipidemia, and metabolic syndrome.
- IC50 of 38 nM for human DGAT-1; 120 nM for rat DGAT-1
- Inhibits human DGAT1 expressed in CHOK1 cells with an EC50 of 0.66 μM
- Blocks the human ether-a-go-go-related gene (hERG) encoded potassium channel with an IC20 of 0.2 μM
- Reduces weight gain and plasma triglycerides, and improves lipid profile (5-50 mg/kg; p.o once daily for three weeks)
- Exhibits good oral bioavailability (77%) and a maximum exposure level in plasma (Cmax) of 24 μM (50 mg/kg; p.o)
- Exhibits terminal elimination half-lives (1.95 h) and low clearance (13.5 mL/min/kg) (5 mg/kg; i.v)